受强制性开放获取政策约束的文章 - Preetesh Jain MBBS,MD,DM,PhD了解详情
无法在其他位置公开访问的文章：6 篇
The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience
P Jain, H Kantarjian, F Ravandi, D Thomas, S O'brien, T Kadia, J Burger, ...
Leukemia 28 (4), 973-975, 2014
强制性开放获取政策： US National Institutes of Health
Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly
O Benjamini, P Jain, Z Estrov, HM Kantarjian, S Verstovsek
Blood, The Journal of the American Society of Hematology 120 (13), 2768-2769, 2012
强制性开放获取政策： US National Institutes of Health
Autologous stem cell transplantation for untreated transformed indolent B‐cell lymphoma in first remission: an international, multi‐centre propensity‐score‐matched study
CK Chin, KJ Lim, K Lewis, P Jain, Y Qing, L Feng, CY Cheah, JF Seymour, ...
British journal of haematology 191 (5), 806-815, 2020
强制性开放获取政策： US National Institutes of Health
Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma
CK Chin, MA Rodriguez, Y Qing, L Feng, F Samaniego, P Jain, M Noorani, ...
Leukemia & lymphoma 61 (12), 2985-2989, 2020
强制性开放获取政策： US National Institutes of Health
Richter's transformation in CLL—a distinct lymphoma
P Jain, KH Young
Nature Reviews Clinical Oncology 11 (1), 6-8, 2014
强制性开放获取政策： US National Institutes of Health
Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy
P Boddu, P Jain, G Borthakur, S Verstovsek, G Garcia-Manero, N Daver, ...
Leukemia & lymphoma 60 (13), 3172-3180, 2019
强制性开放获取政策： US National Institutes of Health
可在其他位置公开访问的文章：83 篇
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
P Jain, M Keating, W Wierda, Z Estrov, A Ferrajoli, N Jain, B George, ...
Blood, The Journal of the American Society of Hematology 125 (13), 2062-2067, 2015
强制性开放获取政策： US National Institutes of Health
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials
K Sasaki, SS Strom, S O'Brien, E Jabbour, F Ravandi, M Konopleva, ...
The Lancet Haematology 2 (5), e186-e193, 2015
强制性开放获取政策： US National Institutes of Health
Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management
P Jain, M Wang
American journal of hematology 94 (6), 710-725, 2019
强制性开放获取政策： US National Institutes of Health
TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes
TM Kadia, P Jain, F Ravandi, G Garcia‐Manero, M Andreef, K Takahashi, ...
Cancer 122 (22), 3484-3491, 2016
强制性开放获取政策： US National Institutes of Health
Targeted therapy in cancer
AM Tsimberidou
Cancer chemotherapy and pharmacology 76 (6), 1113-1132, 2015
强制性开放获取政策： US National Institutes of Health
Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors
P Jain, H Kantarjian, KP Patel, GN Gonzalez, R Luthra, RK Shamanna, ...
Blood, The Journal of the American Society of Hematology 127 (10), 1269-1275, 2016
强制性开放获取政策： US National Institutes of Health
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes
O Benjamini, P Jain, L Trinh, W Qiao, SS Strom, S Lerner, X Wang, ...
Leukemia & lymphoma 56 (6), 1643-1650, 2015
强制性开放获取政策： US National Institutes of Health
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities
P Jain, H Kantarjian, A Nazha, S O’Brien, E Jabbour, CG Romo, S Pierce, ...
Blood, The Journal of the American Society of Hematology 121 (24), 4867-4874, 2013
强制性开放获取政策： US National Institutes of Health
Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients
P Jain, HM Kantarjian, A Ghorab, K Sasaki, EJ Jabbour, ...
Cancer 123 (22), 4391-4402, 2017
强制性开放获取政策： US National Institutes of Health
Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia
XJ Yan, I Dozmorov, W Li, S Yancopoulos, C Sison, M Centola, P Jain, ...
Blood, The Journal of the American Society of Hematology 118 (19), 5201-5210, 2011
强制性开放获取政策： US National Institutes of Health
Long‐term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib
P Jain, PA Thompson, M Keating, Z Estrov, A Ferrajoli, N Jain, ...
Cancer 123 (12), 2268-2273, 2017
强制性开放获取政策： US National Institutes of Health
Malignancy‐associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes
GN Tamamyan, HM Kantarjian, J Ning, P Jain, K Sasaki, KL McClain, ...
Cancer 122 (18), 2857-2866, 2016
强制性开放获取政策： US National Institutes of Health
Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs
P Jain, H Kantarjian, PC Boddu, GM Nogueras-González, S Verstovsek, ...
Blood advances 3 (6), 851-861, 2019
强制性开放获取政策： US National Institutes of Health
Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study
P Jain, H Kantarjian, E Jabbour, GN Gonzalez, G Borthakur, ...
The Lancet Haematology 2 (9), e376-e383, 2015
强制性开放获取政策： US National Institutes of Health
出版信息和资助信息由计算机程序自动确定